Entering text into the input field will update the search result below

AstraZeneca's Lynparza nabs accelerated review in U.S. for prostate cancer

Jan. 21, 2020 6:39 AM ETAstraZeneca PLC (AZN), MRKBy: Douglas W. House, SA News Editor4 Comments
  • The FDA grants Priority Review status to AstraZeneca's (NASDAQ:AZN) Lynparza (olaparib) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations who have progressed following prior treatment with a new hormonal agent.
  • The agency's action date is next quarter.
  • Shares down 2% premarket on light volume.
  • Related ticker: Merck (NYSE:MRK)

Recommended For You

Comments (4)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

SuperPac profile picture
A great stock...had a fantastic 2019 for the right reasons. Keep an eye on this one for opportune position-taking.
5ofDiamonds profile picture
Someone mentioned that while analysts are claiming to invest outside US to find value in Europe/Emerging markets, the top stocks there are also overvalued @SuperPac

$AZN also trading near 52WH.
SuperPac profile picture
It is. But worth nibbling if you spot a 10% correction. Read the last few news items about it in SA. Many good things lined up. GSK too is doing a few good things in its portfolio and how it allocates capital.
5ofDiamonds profile picture
Thanks @SuperPac

I might nibble $AZN to keep it on my radar. 10% corrections are hard to find.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.